Source: Eur Respir J 2008; 31: 927-933
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Suissa S., Ernst P., Vandemheen K. L., Aaron S. D.. Methodological issues in therapeutic trials of COPD. Eur Respir J 2008; 31: 927-933

Member's Comments

No comment yet.

Related content which might interest you: Methods for therapeutic trials in COPD: lessons from the TORCH trial Source: Eur Respir J 2009; 34: 1018-1023 Year: 2009 Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study Source: Eur Respir J 2010; 35: 532-539 Year: 2010 Medication use in COPD: systematic review and meta-analysis Source: Annual Congress 2007 - Treatment and care of COPD Year: 2007 Need for generalized criteria in evaluating the impact of new drugs in clinical trials involving patients suffering from COPD Source: Annual Congress 2006 - Outcomes for COPD pharmacological trials: from lung function to biomarkers Year: 2006 Observational studies assessing the pharmacological treatment of obstructive lung disease: strengths, challenges and considerations for study design Source: ERJ Open Res, 6 (4) 00044-2020; 10.1183/23120541.00044-2020 Year: 2020 The utility of tiotropium among patients with chronic obstructive pulmonary disease (COPD): An updated meta-analysis of randomized controlled trials Source: Annual Congress 2013 –Quality of diagnosis and assessment in primary care Year: 2013 Premature discontinuation of patients: a potential bias in COPD clinical trials Source: Eur Respir J 2007; 30: 898-906 Year: 2007 How to increase the value of randomised trials in COPD research Source: Eur Respir J 2009; 34: 552 Year: 2009 Can roflumilast improve clinical outcomes in moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis Source: International Congress 2016 – COPD diagnosis and management Year: 2016 Influence of patient baseline characteristics and concomitant medication on outcomes in long-term trials of COPD: Analysis of the UPLIFT® trial Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Baseline data and responses to oral steroid intervention in asthma and COPD: interim report from the BIOAIR EU study Source: Annual Congress 2007 - Asthma subphenotypes Year: 2007 The patient’s role in the choice of new inhaler devices and dosing regimens for asthma and COPD: A preference study Source: International Congress 2016 – Kaleidoscope of respiratory nursing Year: 2016 Long-acting bronchodilator initiation in COPD and cardio-pulmonary risks: A population-based comparative effectiveness study Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 The future of disease monitoring and management: the homework for clinical researchers Source: Annual Congress 2005 - Inflammatory phenotypes of asthma and COPD: the end of traditional diagnosis, or not? Year: 2005 Withdrawal of inhaled corticosteroids in people with chronic obstructive pulmonary disease (COPD) in primary care – a randomised controlled trial Source: Annual Congress 2005 - Effects of anti-inflammatory drugs on COPD Year: 2005 Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease Source: Eur Respir J 2001; 18: 903-908 Year: 2001 The healthcare burden of non-compliance to pharmacotherapeutic escalation recommendations for COPD Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Onbrace: A real-life evaluation of indacaterol maintenance treatment for COPD Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 Safety and benefits of beta-blockers in chronic obstructive pulmonary disease: a review of current evidence and meta-analysis Source: International Congress 2018 – Cardiovascular morbidities in COPD Year: 2018